Thursday, November 12, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 28, 2026

Meta Reports Fourth Quarter and Full Year 2025 Results

View original at finance.yahoo.com
“Three Months Ended December 31 ... Revenue $ 59,893 $ 48,385 24 % $ 200,966 $ 164,501 22 % (also: "Revenue was $59.89 billion and $200.97 billion ... for the fourth quarter and full year 2025")”
Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Continue to monitor legal and regulatory headwinds in EU and US that could significantly impact business and financial results

    80% confidence

  • Looking forward to advancing personal superintelligence for people around the world in 2026

    80% confidence

  • 2026 capital expenditures expected to be in the range of $115-135 billion, driven by Meta Superintelligence Labs efforts

    80% confidence

  • Majority of expense growth will be driven by infrastructure costs, including third-party cloud spend, higher depreciation, and higher infrastructure operating expenses

    80% confidence

  • Absent any changes to tax landscape, expect full year 2026 tax rate to be 13-16%

    80% confidence

  • First quarter 2026 total revenue expected to be in the range of $53.5-56.5 billion

    80% confidence

  • We had strong business performance in 2025

    80% confidence

  • Full year 2026 total expenses expected to be in the range of $162-169 billion

    80% confidence

  • Absent the valuation allowance charge as of enactment date, full year 2025 effective tax rate would have decreased by 17 percentage points to 13%

    80% confidence

  • Despite meaningful step up in infrastructure investment, in 2026 we expect to deliver operating income that is above 2025 operating income

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com